Patents Expiring Will Propel Growth of Generics In Neurodegenerative Drugs Market

Patents expiring will propel growth of generics in neurodegenerative drugs market.

(PRWEB) August 12, 2007 -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report on the latest developments in the neurodegenerative disease and drug market.

"Neurodegenerative Disease Drug Market Analysis and Forecasts 2007" finds that drug trials in the neurodegenerative sector have yielded hopeful results, suggesting that the market is set for expansion. The report reveals that the Neurodegenerative market was worth over $16 billion in 2006, with growth anticipated to exceed $18 billion in 2007.

The report is a comprehensive study on the major neurodegenerative
diseases- Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis and Neuropathic pain. It also looks at rarer genetic disorders like Huntington Disease as well the progressive neurodegenerative disease Amyotrophic Lateral Sclerosis. It records how these diseases place financial pressures on national healthcare services.

Authors of the report explain that there is a worldwide ageing of the Baby Boom generation, coupled with a rise in longevity. These factors are major catalysts in the long-term revenue growth in the pharmaceutical/health care sector, they claim.

The study analyses periods of sustained revenue growth in the 2007-2012 timeframe, and turns the spotlight on how patents expiring on major blockbuster drugs in the neurodegenerative segment in 2012, will boost the revenues in the generics market.

Market leaders like Biogen Idec, Elan, Eli Lilly, Novartis and Pfizer are expected to see major leaps in global annual earnings following advancements in the pharmaceutical and healthcare sector, say the authors.

Analysts have addressed key issues affecting the neurodegenerative market such as exploring whether stem cell research is the answer to these diseases. They have also predicted the most successful drugs in the next five years, and highlighted the current therapies that show the most revenue generating potential.

The report pinpoints the regions that show the highest prevalence of the diseases today and extrapolate available data to make predictions of disease incidence up to 2020. It also profiles the market leaders in neurodegenerative therapy, outlines current approved therapies and identifies the first line drugs coming off patent by 2012. The study values the market for 2007 and forecasts how much it will be worth in the next five years.

"Neurodegenerative Disease Drug Market Analysis and Forecasts 2007" is available in pdf format from Piribo. For more information, go to:
http://www.piribo.com/publications/g...asts_2007.html

Piribo product ID: VIS055

About Piribo.
Piribo (http:www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

http://www.prweb.com/releases/2007/8/prweb546089.htm